

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6916039

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AMICOAT AS	07/21/2021
RECEIVING PARTY DATA	
Name:	PEPTIDE PATENTS AS
Street Address:	SYKEHUSVEGEN 23
City:	TROMSO
State/Country:	NORWAY
Postal Code:	NO-9019
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	13122156
Application Number:	15391167
Application Number:	16400307
Application Number:	17116054
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	ipdocket@foxrothschild.com
Correspondent Name:	FOX ROTHSCHILD LLP
Address Line 1:	997 LENOX DRIVE
Address Line 4:	LAWRENCEVILLE, NEW JERSEY 08648
ATTORNEY DOCKET NUMBER:	084283.00013
NAME OF SUBMITTER:	KRISTA COFFEY
SIGNATURE:	/Krista Coffey/
DATE SIGNED:	09/14/2021
Total Attachments: 3	
source=105 Assignment#page1.tif	
source=105 Assignment#page2.tif	
source=105 Assignment#page3.tif	

PATENT ASSIGNMENT

This assignment is made the 21/3 day of July / August 2021, but regarded as effective from 1 January 2019 ("Effective Date"), by and between Amicoat AS, organization number 913 811 380, Sykehusvegen 23, 9019 Tromsø (hereinafter the "Assignor"), and Peptide Patents AS, organization number 922 687 374, Sykehusvegen 23, NO-9019 Tromsø, Norway, (hereinafter the "Assignee"); together the "Parties" and individually a "Party".

WHEREAS

- (1) The Assignor was originally the owner of and had full title to certain patents, which included the "Patents" (as defined in Appendix 1);
- (2) The Assignor transferred the rights, title and interest in and to these patents – which definition also includes any ancillary documentation and know-how – to the Assignee under a patent assignment agreement dated 8 April 2019 (the "2019 Patent Assignment Agreement");
- (3) The Parties also entered into a license agreement on 8 April 2019 (the "2019 License Agreement") in relation to the same patents, whereby the rights to the patents for any purpose, product and process except any kind of purpose, product and process for pharmaceuticals for use as drugs or medications (the "Field of Use" as defined in the 2019 License Agreement) were licensed back to the Assignor;
- (4) This patent assignment agreement (the "2021 Patent Assignment Agreement") sets out and restates the conditions of assignment of the rights to the Patents from Assignor to Assignee. This 2021 Patent Assignment Agreement supersedes the 2019 Patent Assignment Agreement in every way in respect of the Patents.

NOW THEREFORE; in consideration of the sum of 400,000 (fourhundredthousand) Norwegian Kroner (ex. VAT) and other good and valuable consideration paid by the Assignee to the Assignor (for the Patents as well as the other patents originally transferred under the 2019 Patent Assignment Agreement), the receipt and sufficiency whereof is hereby acknowledged, the Assignor hereby assigns and transfers to the Assignee all rights, title and interest in and to the Patents, including the right to claim priority from the priority application and to apply for and be granted patents or other

120612886.v1

intellectual property rights in relation to the Patents, to hold absolutely ownership in and title to these rights.


The Assignor further covenants with the Assignee to sign all such documents as are necessary for the Assignee to enjoy to the full the rights hereby assigned and transferred.

Any term not specifically defined in this 2021 Patent Assignment Agreement shall hold the meaning as set out in the 2021 License Agreement, as set out in Appendix 2 (entered into immediately subsequent to the patent assignment under the 2021 Patent Assignment Agreement), to the extent therein defined.



This 2021 Patent Assignment Agreement and the legal relationship between the Parties shall be governed by Norwegian law. Any dispute, controversy or claim arising out of, or relating to, this 2021 Patent Assignment Agreement, or the breach, termination or invalidity thereof, which cannot be resolved through discussions between the Parties shall be settled by the ordinary courts on Norway, Oslo City Court (Nw.: Oslo tingrett) as legal venue.

In witness whereof this 2021 Patent Assignment Agreement has been executed by the Parties hereto as of the date first set out above.

Amicoat AS

By: 
Georg Andreas Gundersen (CEO)

Peptide Patents AS

By:  
Erik Rosen Christian Georg Lütken
(chairman) (board member)

Appendix 1: The Patents
Appendix 2: 2021 License Agreement

Appendix 1 – the Patents:

1. U.S. Application serial number 13/122156 (now patent number 9556223)
2. U.S. Application serial number 15/391,167
3. U.S. Application serial number 16/400307
4. U.S. Application serial number 17/116054

The definition of the Patents includes, in addition to the 4 abovementioned US patents/applications, any continuations and divisionals thereof.